



News Release Dated October 30, 2019

MEDRx Co., Ltd.
Yonehiro Matsumura, CEO
Stock code: 4586, TSE Mothers

MEDRx Announces Termination of Technology License Agreement with Takeda

MEDRx Co. Ltd. announces today that the technology license agreement with Takeda Pharmaceutical Company Limited for the development of one or more transdermal medicines of certain Takeda's pipeline products in a therapeutic area has terminated.

Under the agreement, MEDRx and Takeda had evaluated novel formulations for one or more compounds using MEDRx's proprietary technology, but the results of the evaluation could not meet certain criteria.

Contact:
MEDRx Co., Ltd.
Management Department
E-mail: info@medrx.co.jp
